Donald C Moore

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 22

Top Topics

Multiple Myeloma

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Clinical Practice

Top Venues

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

The Annals of pharmacotherapy

JCO precision oncology

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

D Grace Nguyen, Sarah A Morris, Alicia Hamilton, Simeon O Kwange, Nury Steuerwald, James Symanowski, Donald C Moore, Sarah Hanson, Kaitlyn Mroz, Karine E Lopes, Chris Larck, Laura Musselwhite, Kunal C Kadakia, Brinda Koya, Seungjean Chai, Kwabena Osei-Boateng, Sini Kalapurakal, Kristen Swift, Jimmy Hwang, Jai Narendra Patel
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase ( DPYD ) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center. JCO precision oncology 8 (2024)
D Grace Nguyen, Sarah A Morris, Alicia Hamilton, Simeon O Kwange, Nury Steuerwald, James Symanowski, Donald C Moore, Sarah Hanson, Kaitlyn Mroz, Karine E Lopes, Chris Larck, Laura Musselwhite, Kunal C Kadakia, Brinda Koya, Seungjean Chai, Kwabena Osei-Boateng, Sini Kalapurakal, Kristen Swift, Jimmy Hwang, Jai Narendra Patel
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase ( DPYD ) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center. JCO precision oncology 8 (2024)
Caroline Fleck, Allison Karabinos, Allene Cook, Donald C Moore, Ryan Jacobs
Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia. Leukemia & lymphoma (2024)
Caroline Fleck, Allison Karabinos, Allene Cook, Donald C Moore, Ryan Jacobs
Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia. Leukemia & lymphoma 65 (8) (2024)
Donald C Moore, Joseph B Elmes, Justin R Arnall, Scott A Strassels, Jai N Patel
Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis. International journal of clinical pharmacy (2023)
Donald C Moore, Keren A Eagers, Amanda Janes, Mauricio Pineda-Roman
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
Donald C Moore, Joseph B Elmes, Justin R Arnall, Scott A Strassels, Jai N Patel
Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system. Haemophilia : the official journal of the World Federation of Hemophilia 28 (5) (2022)
Justin R Arnall, Donald C Moore, Meghan Michael, Michael Wolcott, Nicole Cowgill
Measuring the Impact of a Pharmacist-Driven Blood Factor Education Program: A Prospective, Single-Center Observational Study. Hospital pharmacy 58 (3) (2022)
Donald C Moore, Matthew R Peery, Katherine A Tobon, Farah Raheem, Grace S Hwang, Lin Alhennawi, Mitchell E Hughes
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 28 (8) (2022)
Paul Christopher Parish, Donald C Moore, Megan Wayman, Justin R Arnall
Evaluation of Pharmacist Impact on Patients Initiating Eculizumab for Atypical Hemolytic Uremic Syndrome in the Inpatient Setting. The Annals of pharmacotherapy (2022)
Donald C Moore, Justin R Arnall
Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis. The Annals of pharmacotherapy (2022)
Donald C Moore, Joseph B Elmes, Tsion Gebru, Lesli A Lavery, Annie Pellegrino, Dragos Plesca
Implementation, utilization, and evaluation of a pharmacist-driven romiplostim dosing service for patients with immune thrombocytopenia at a multisite cancer centre. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 28 (3) (2022)
Justin R Arnall, Kathryn T Maples, R Donald Harvey, Donald C Moore
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations. The Annals of pharmacotherapy 56 (8) (2021)
Kiley M Wooten, Justin R Arnall, Kiarra M Bowser, Laurie J Pennell, Jazmin N Wade-Davis, Jacqueline L Olin, Margaret Taylor, Donald C Moore
Publication rates of hematology/oncology abstracts presented at major pharmacy association meetings. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Alana M Ciolek, Justin Arnall, Donald C Moore, Surabhi Palkimas, Julie Der-Nigoghossian, Kathryn E Dane
Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice. The Annals of pharmacotherapy (2021)
Donald C Moore
Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Donald C Moore, Amy C Soni, Bei Hu, Elton T Smith, Jonathan Levine, Tamara K Moyo, Ryan Jacobs, Nilanjan Ghosh, Steven I Park
Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. British journal of haematology (2021)
Anna Lee, Chris Larck, Donald C Moore
Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 28 (1) (2020)
Amani M Cobert, Catherine Helms, Chris Larck, Donald C Moore
Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis. Therapeutic advances in drug safety 11 (2020)
Donald C Moore, Tsion Gebru, Dragos Plesca
Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Jolly Patel, Rebecca Ann Rainess, Miranda J Benfield, Kate M L Rogers, Donald C Moore, Chris Larck, Justin R Arnall
Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support. Hospital pharmacy 56 (2) (2019)
Donald C Moore, Joseph B Elmes, Priscila A Shibu, Chris Larck, Steven I Park
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. The Annals of pharmacotherapy 54 (4) (2019)